Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

1 results
2:10 PM, Nov 27, 2017  |  BC Extra | Clinical News

Regeneron discontinues Eylea/nesvacumab combo

data from the trials before deciding on how to proceed with nesvacumab, a mAb against angiopoietin 2
ANG2; ANGPT2). He said Regeneron has not disclosed whether the candidate is in testing for other …